NCT05063877View on ClinicalTrials.gov

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

PHASE2UnknownINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

October 11, 2022

Study Completion Date

October 11, 2023

Conditions
Epilepsy
Interventions
DRUG

Placebo

Matched placebo

DRUG

EQU-001

EQU-001 in 10 mg and 20 mg capsules

Trial Locations (10)

10016

NYU Langone Medical Center, NYU Comprehensive Epilepsy Center, New York

19107

Comprehensive Epilepsy Center at Thomas Jefferson University, Philadelphia

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

22903

University of Virginia, Charlottesville

83702

Consultants in Epilepsy and Neurology PLLC, Boise

4941492

Rabin Medical Center, Petah Tikva

5262000

Chaim Sheba Medical center, Ramat Gan

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

9112001

Hadassah Medical Center, Jerusalem

07601

Northeast Regional Epilepsy Group, Hackensack

Sponsors
All Listed Sponsors
lead

Equilibre Biopharmaceuticals B.V.

INDUSTRY